| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidateCandidate's Name , PhDHighly Motivated, Independent and Experienced NeuroscientistBoston, MA; email: EMAIL AVAILABLE; cell phone: PHONE NUMBER AVAILABLE First author in Neuron (2023), Nature (2019) and Nature Communications (2016) Organized, communicative, adaptable and proactive in prioritizing tasks and managing multiple projects Can achieve deliverables in a timely manner Excels at technical troubleshooting and protocol development, validation, and optimizationWork ExperienceScientist II Ovid TherapeuticLab in Tufts Launchpad Biolab, Boston, MA <Dec 2020 to Feb 2024> My Bench work in Ovid mainly involved three pipelines: OV329, OV350 (both are small molecules targeting GABA-aminotransferase and KCC2 transporter) and OV882 (gene therapy targeting iPSC from rare human disease patients). I have been leading the in vivo strategy, designing and implementing the studies both in-house and through managing external work at CROs. My PK/PD/Toxicology/Biomarker data play an important role in the IND approval for OV329 in October 2022 (see reference 1) and the coming IND Co-filing documents for OV350 this year. One important side effect of OV329 is retinotoxicity so I did plenty bio-informative research on different subtype of retinal cells and provided one type of Muller cells was responsible for the toxicology. Biomarker screening by MSD/ELISA/ddPCR and subsequent verified via Intraventricular & intravitreal injection, tissue sections and IHC/in situ were also successful in my hands. Lead as technical supervisor and mentor of junior scientist. As a co-project manager, I organized regular meeting with whole R&D team in Boston and Clinical team in New York. This helped me familiar with key steps how industrial company progressed and the detail process of drug development. I got trained and certificated in GLP, ELN documentation and an Outstanding Scientist Award in Ovid. Within these years, I had handled many CROs including one efficacy study of OV329 in reducing seizure using mouse MTLE in Psychogenics, four PK studies using LC/MS to detect OV329 in WuXi and three Tox studies using different chronic dose of OV329 in Charles River. For OV350, I did the preliminary PK in WuXi using LC/MS and some in-house behavioral screening (seizure, pain and psychosis) in mice using Tufts Launchpad Bio-labs mouse facility. Each CRO cases covered writing proposals, finding vendors, organizing meeting and writing reports. Frequent communication/cooperation with our internal clinical team is also a significant portion of my current job since OV329 is now already in Phase Ib clinical trial. In OV882, I did culture screening using both AAVs and ASOs in patient neurons derived from iPSC and found the best target to do RNAi/ASO gene therapy. The iPSC derived neuron culture involved 2D culture with fibroblast/glia cell in the Petri dish.Research fellow Dana Farber Cancer Institute and Harvard Medical school - Boston, MA <Apr 2016 to Dec 2020> Expert researcher in mouse genetic and specialized CRISPR/Cas9 gene editing in mouse embryos. I was well trained in techniques covering from molecular cloning, cell culture, molecular biology and in vivo electrophysiological and behavioral phenotyping. My project at this period was focused on dissecting the neuronal circuits from the DRG, spinal cord and ascending to the brain, in mediating visceral/cancer pain under inflammation/PDX conditions. I had more than 5 years in-hand experience in packing AAVs from plasmids and subsequent in vivo surgery to drive target protein in the CNS. My research findings in visceral/cancer pain were awarded with the R01 NIH grant and published as co-first author in Nature 2019 & Neuron 2023.Postdoctoral Researcher Institute of Biomedical Science, Academia Sinica, Taiwan <May 2015 to Feb 2016> The post-Doc is an extension of my PhD career in Dr. Chih-Cheng Chen's lab in the Institute of Biomedical Science, Academia Sinica, Taiwan. In PhD, I had generated over ten strains of Cre/loxp transgenic mouse models covering almost all members of the Acid-Sensing Ion channels (ASICs) family; see my first author review paper in Neuropharmacology, 2015. I am well-trained in techniques including plasmid vector cloning; ES cell targeting using traditional gene targeting, TALEN and CRISPR/Cas9 technique. I can operate mouse pronuclear DNA, blastocyst ES cell microinjection and oviduct embryos transfer under microscope. My achievements at this stage are functional characterization of many ASIC mouse models I generated on my own, from in vitro neurons culture, ex vivo muscle-nerve recording to in vivo behavioral phenotyping. Mice metabolic cage/blood pressure/sugar/EEG experiments were routinely performed due to they are important phenotypes of ASICs KO. Confocal microscopy, DRG neuron Ca-imaging and Microdialysis/HPLC are also routinely used at this moment. As a senior post-Doc, I instructed more than 10 graduated students and some of our findings were recently published in every year SfN meeting and related top journals, see Nature Communications 2016.EducationDoctorate in Life ScienceNational defense medical center TaiwanMaster in NeuropharmacologyNational Taiwan University TaiwanBachelor in PsychologyNational Cheng-Chi University TaiwanSkills (Bold letters: +5 years experience)Genetic tools engineering (CRISPR/TALAN/AAV/Lentiviral plasmid vector engineering) Transgenic Mouse behavioral phenotyping Molecular cloning Electrophysiological recording Mouse stereotaxic surgery and tissues collection In vivo rodent dosing IP, IV, SC, PO, IT, ICV Mouse pronuclear DNA /blastocyst ES cell microinjection Mouse oviduct embryo transfer/ sperm cryopreservation Inflammation/cancer neuropharmacology rodent models Rodent cardiovascular/metabolic cage in vitro Ca-imaging/in vivo EMG/EEG recording Fluorescence/Confocal microscopy Flow cytometry using transgenic reporter labeled primary DRG neurons ICC, IHC, ELISA, Western, Co-IP & in situ hybridization High-Performance Liquid Chromatography & In vivo Microdialysis in rodent brain Realtime/RT-PCR/ddPCR Primary neuron/glia, 2D-iPSC & mouse ES cell culture CRO project management ELN work GLP training certificate Expert level in Experimental design and Statistics (EXCEL, SAS, SPSS & Prism)SELECTED PUBLICATIONSLin SH, Vecchione A. Colburn R. Mukherjee J. Sarmiere P. Low, repeat dosing of OV329 enhances GABA-AT inhibition in rodent brain-relationship between pharmacokinetic and pharmacodynamic effects. Poster #3.255 American Epilepsy Society (AES) annual meeting in Orlando, 2023 Dec.Lee CH, Sun SH, Lin SH, Chen CC. Role of the acid-sensing ion channel 3 in blood volume control. Circ J. 2011; 75:874-83. Chen WN, Lee CH, Lin SH, Wong CW, Sun WH, Wood JN, Chen CC. Roles of ASIC3, TRPV1, and NaV1.8in the transition from acute to chronic pain in a mouse model of fibromyalgia. Mol Pain. 2014 Jun 23;10 Lin SH, Sun WH, Chen CC. Genetic exploration of the role of acid-sensing ion channels. Neuropharmacology. 2015 Jul; 94:99-118. Review Lin SH, Chien YC, Chiang WW, Liu YZ, Lien CC, Chen CC. Genetic mapping of ASIC4 and contrasting phenotype to ASIC1a in modulating innate fear and anxiety. Eur J Neurosci. 2015 Jun; 41(12):1553-68. Lin SH, Cheng YR, Banks RW, Min MY, Bewick GS, Chen CC. Evidence for the involvement of ASIC3 in sensory mechanotransduction in proprioceptors. 2016, Nature communications. 2016, 7, 11460. Lin SH, Steinhoff M, Ikoma A, Chang YC, Cheng YR, Kopparaju RC, Ishii S, Sun WH, Chen CC. Involvement of TRPV1 and TDAG8 in pruriception associated with noxious acidosis. Journal of Investigative Dermatology, 2017, 137 (1), 170-178. Huang TW*, Lin SH*, Malewicz NM, Zhang Y, Zhang Y, Goulding M, LaMotte RH and Ma Q. Identifying the pathways required for coping behaviours associated with sustained pain. Nature. 2019 Jan;565(7737):86-90(* contribute equally). Wu WL*, Cheng S*, Lin SH*, Chuang YC, Huang YK and Chen. CC The Effect of ASIC3 Knockout on Corticostriatal Circuit and Mouse Self-grooming Behavior. Frontiers in Cellular Neuroscience. 2019, 13, 86. Chang CT, Fong SW, Lee CH, Chuang YC, Lin SH*, Chen CC*. Involvement of Acid-Sensing Ion Channel 1b in the Development of Acid-Induced Chronic Muscle Pain. Front Neurosci. 2019 Nov 22; 13:1247. (* Co-corresponding) Sakai K, Sanders KM, Lin SH, Pavlenko D, Funahashi H, Lozada T, Hao S. Low-threshold mechanosensitive VGLUT3-lineage sensory neurons mediate spinal inhibition of itch by touch. Journal of Neuroscience 40 (40), 7688-7701, 2020 Han DS, Lee CH, Shieh YD, Chang CT, Li MH, Chu YC, Wang JL, Chang KV, Lin SH#, Chen CC#. A role for substance P and acid-sensing ion channel 1a in prolotherapy with dextrose-mediated analgesia in a mouse model of chronic muscle pain. Pain Aug 9. 2021. (# co-corresponding) Lu Q*, Lin SH*. and Ma Q. Spinal VGLUT3 lineage neurons drive visceral mechanical allodynia but not sensitized visceromotor reflexes. Neuron 2023, Mar 1;111(5):669-681. |
